More GLP-1 drugs
Other drugs that act on the GLP-1 receptor: daily and weekly shots, some no longer sold, one approved outside the US, and a GLP-1 pill that isn't a peptide.
In this group
- LiraglutideA once-a-day GLP-1 shot, sold as Victoza for type 2 diabetes and as Saxenda for weight management.Approved by the FDA in 2010 for type 2 diabetes, as Victoza, and in 2014 for weight management, as Saxenda; generic versions of both are approved.
- DulaglutideA once-a-week GLP-1 shot, built by joining a GLP-1-like chain to part of an antibody.Approved by the FDA in 2014 for type 2 diabetes, as Trulicity.
- ExenatideA GLP-1 drug originally found in the venom of the Gila monster, a lizard.Approved by the FDA in 2005 for type 2 diabetes, as Byetta, and now listed by the FDA as discontinued, along with every form of Bydureon and the one generic version of Byetta.
- LixisenatideA once-a-day GLP-1 that, in the US, now comes only mixed with insulin, as Soliqua.Approved by the FDA in 2016 for type 2 diabetes, as Adlyxin and as part of Soliqua; the FDA now lists Adlyxin as discontinued, so in the US it comes only in Soliqua.
- AlbiglutideA weekly GLP-1 shot that its maker stopped selling worldwide, saying the reasons were commercial.Approved by the FDA in 2014 for type 2 diabetes, as Tanzeum, and now listed by the FDA as discontinued.
- OrforglipronA GLP-1 pill that isn't a peptide, approved in the US as Foundayo.Approved by the FDA in 2026 for long-term weight management, as Foundayo.
- EfpeglenatideA GLP-1 shot based on a peptide first found in Gila monster venom, approved in South Korea.Approved in South Korea in October 2026 for weight management in adults without diabetes; not approved by the FDA.
Related: The GLP-1 family
Get an early invite to Tidepath
The app isn't in the App Store yet. Leave your email for an early invite, and tips for your first month.
Get an early invite, tips and occasional news from Tidepath. Unsubscribe anytime. Privacy · Health data privacy · Sender and contact details